MedPath

Avastin for CNV Secondary to Pattern Dystrophy

Phase 2
Conditions
Choroidal Neovascularization Secondary to Pattern Dystrophy
Registration Number
NCT00391144
Lead Sponsor
University of Trieste
Brief Summary

The natural history of subfoveal CNV secondary to Pattern Dystrophy is little understood, but it seems that visual function may be preserved only in the short-term follow-up, with progressive deterioration thereafter.

Photodynamic therapy with verteporfin is the most studied therapeuthic option for this kindf of lesion, but unfortunately, this approach does not appear to guarantee long-term vision stabilization, and alternative therapies should be investigated.

Detailed Description

Diagnosis of Pattern Dystrophy Diagnosis of subfoveal CNV Intravitreal injection of avastin (1.25 mg) in operating room under sterile condition.

Retreatment on the basis of the detection of disease progression and of lack of central retinal thickness reduction on OCT.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
5
Inclusion Criteria
  • diagnosis of RPD (hyperpigmented yellowish-greyish network, other family members sharing RPD, normal electroretinogram and normal/subnormal electrooculogram)
  • classic or occult CNV involving the foveal avascular zone's geometric centre
Exclusion Criteria
  • conditions other than RPD
  • intraocular surgery or capsulotomy within the last 2 or 1 months
  • pregnancy

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
number of eyes with <15 letter loss (approximately <3 lines) at 6-month examination compared with the baseline value
numeber of eyes with <15 letter loss at 12-month examinations, compared with the baseline value.
Secondary Outcome Measures
NameTimeMethod
CNV progression
number of injections.

Trial Locations

Locations (1)

Clinica Oculistica, Azienda Ospedaliero-Universitaria di Trieste

🇮🇹

Trieste, TS, Italy

© Copyright 2025. All Rights Reserved by MedPath